Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome - PubMed

Affiliations

• PMID: 29880241
• DOI: 10.1016/j.vaccine.2018.05.119

Review

Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome

Nicola Principi et al. Vaccine. 2019.

Abstract

Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy. Infections and vaccines have been hypothesized to play a role in triggering GBS development. These beliefs can play a role in reducing vaccination coverage. In this report, data concerning this hypothesis are discussed. It is shown that an association between vaccine administration and GBS has never been proven for most of debated vaccines, although it cannot be definitively excluded. The only exception is the influenza vaccine, at least for the preparation used in 1976. For some vaccines, such as measles/mumps/rubella, human papillomavirus, tetravalent conjugated meningococcal vaccine, and influenza, the debate between supporters and opponents of vaccination remains robust and perception of vaccines' low safety remains a barrier to achieving adequate vaccination coverage. Less than 1 case of GBS per million immunized persons might occur for these vaccines. However, in some casesimmunization actually reduces the risk of GBS development. In addition, the benefits of vaccination are clearly demonstrated by the eradication or enormous decline in the incidence of many vaccine-preventable diseases. These data highlight that the hypothesized risks of adverse events, such as GBS, cannot be considered a valid reason to avoid the administration of currently recommended vaccines.

Keywords: Guillain-Barrè syndrome; Human papillomavirus vaccine; Influenza; Measles/mumps/rubella vaccine; Safety; Tetravalent conjugated meningococcal vaccine.

Similar articles

• Principal Controversies in Vaccine Safety in the United States.

  DeStefano F, Bodenstab HM, Offit PA. DeStefano F, et al. Clin Infect Dis. 2019 Aug 1;69(4):726-731. doi: 10.1093/cid/ciz135. Clin Infect Dis. 2019. PMID: 30753348

• Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination.

  Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H. Patja A, et al. J Pediatr. 2001 Feb;138(2):250-4. doi: 10.1067/mpd.2001.111165. J Pediatr. 2001. PMID: 11174624

• Vaccines and Guillain-Barré syndrome.

  Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Haber P, et al. Drug Saf. 2009;32(4):309-23. doi: 10.2165/00002018-200932040-00005. Drug Saf. 2009. PMID: 19388722 Review.

• Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.

  Vellozzi C, Iqbal S, Broder K. Vellozzi C, et al. Clin Infect Dis. 2014 Apr;58(8):1149-55. doi: 10.1093/cid/ciu005. Epub 2014 Jan 9. Clin Infect Dis. 2014. PMID: 24415636 Review.

Cited by

• COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.

  Mahroum N, Lavine N, Ohayon A, Seida R, Alwani A, Alrais M, Zoubi M, Bragazzi NL. Mahroum N, et al. Front Immunol. 2022 Jul 5;13:872683. doi: 10.3389/fimmu.2022.872683. eCollection 2022. Front Immunol. 2022. PMID: 35865539 Free PMC article. Review.

• Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes?

  Principi N, Esposito S. Principi N, et al. Front Public Health. 2020 Jul 28;8:361. doi: 10.3389/fpubh.2020.00361. eCollection 2020. Front Public Health. 2020. PMID: 32850592 Free PMC article. Review.

• A comparison between online social media discussions and vaccination rates: A tale of four vaccines.

  Chen Q, Croitoru A, Crooks A. Chen Q, et al. Digit Health. 2023 Feb 8;9:20552076231155682. doi: 10.1177/20552076231155682. eCollection 2023 Jan-Dec. Digit Health. 2023. PMID: 36776405 Free PMC article. Review.

• Guillain-Barré Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report.

  Rossetti A, Gheihman G, O'Hare M, Kosowsky JM. Rossetti A, et al. J Emerg Med. 2021 Dec;61(6):e141-e145. doi: 10.1016/j.jemermed.2021.07.062. Epub 2021 Aug 7. J Emerg Med. 2021. PMID: 34538679 Free PMC article.

• Toxicologic Pathology Forum: Tissue Evaluation in Nonclinical Toxicity Studies for Prophylactic Vaccines.

  Sellers RS. Sellers RS. Toxicol Pathol. 2023 Jan;51(1-2):77-80. doi: 10.1177/01926233231163474. Epub 2023 Apr 21. Toxicol Pathol. 2023. PMID: 37083209 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information